Torrent Pharmaceuticals, a prominent drug manufacturer, has received demand notices from the National Pharmaceutical Pricing Authority (NPPA) totaling over Rs 6.63 crore. The notices, issued under Para 15 of the Drug Price Control Order 2013 (DPCO), impose a penalty on the company for allegedly overcharging for five drugs between January 2016 and November 2018. According to a regulatory filing made by the company on Saturday, the demand notices were dated September 29 and October 1, and were received by Torrent Pharmaceuticals on October 3, 2025.
The NPPA’s decision to issue demand notices to Torrent Pharmaceuticals is a significant development, as it highlights the regulatory authority’s efforts to ensure that drug prices are controlled and that pharmaceutical companies comply with the provisions of the DPCO. The penalty imposed on Torrent Pharmaceuticals is substantial, and it is likely to have implications for the company’s financials and operations.
However, according to the company’s assessment, the demand notices are not expected to have a material impact on its financials, operations, or other activities. This suggests that Torrent Pharmaceuticals is confident that it can absorb the penalty and continue to operate without any significant disruptions. The company’s assessment is likely based on its internal review of the demand notices and its evaluation of the potential financial implications.
As a reliable and trusted news source, it is essential to note that the demand notices issued to Torrent Pharmaceuticals are a reminder of the importance of regulatory compliance in the pharmaceutical industry. The NPPA’s actions demonstrate its commitment to ensuring that drug prices are fair and reasonable, and that pharmaceutical companies are held accountable for any violations of the DPCO. The development is also a testament to the effectiveness of the regulatory framework in India, which is designed to protect the interests of consumers and promote fair competition in the pharmaceutical industry.
In conclusion, the demand notices issued to Torrent Pharmaceuticals by the NPPA are a significant development that highlights the importance of regulatory compliance in the pharmaceutical industry. While the company has stated that the demand notices are not expected to have a material impact on its financials or operations, the development is a reminder of the need for pharmaceutical companies to ensure that they comply with the provisions of the DPCO and other regulatory requirements. As a reliable and trusted news source, we will continue to monitor the situation and provide updates as more information becomes available.